Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities

Certara Acquires Vyasa Analytics

January 4, 2023

AI & Machine Learning

Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.

Certara Acquires Applied BioMath

December 14, 2023

Biotechnology

Certara, Inc. has acquired Applied BioMath to expand its biosimulation capabilities and establish the life sciences industry's largest quantitative systems pharmacology (QSP) center of excellence. The acquisition combines Certara's biosimulation and AI portfolios with Applied BioMath's proprietary QSP platform and modeling expertise to industrialize QSP and accelerate drug development.

Certara Acquires Pinnacle 21

October 4, 2021

Software

Certara, Inc. completed the acquisition of Pinnacle 21, a provider of SaaS solutions for clinical data standardization, validation and regulatory-submission readiness. Equity holders of Pinnacle 21 received approximately $250 million in cash and 2,239,717 restricted shares of Certara common stock; Certara said the deal expands its data-sciences and software capabilities and is expected to be accretive to revenue and adjusted EBITDA.

Sygnature Discovery Acquires NuChem Sciences

August 1, 2023

Biotechnology

UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Arranta Bio Acquires Captozyme

November 13, 2019

Biotechnology

Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.